This was the stock's third consecutive day of gains.

The US Department of Agriculture (USDA) has granted conditional approval for a new bird flu vaccine for poultry.

Zoetis was granted a conditional license for its avian influenza vaccine for use in chickens. It's a step closer to fighting ...

Zoetis' Q4 earnings met expectations, but the stock fell due to slowing growth and cautious 2025 guidance. Click here to find ...

Both of these metrics are at their most attractive levels in the company's history, making this a once-in-a-decade opportunity. Its discounted price combined with a long track record of steady growth, ...

Zoetis slightly topped analyst estimates for profitability and met those for revenue in its fourth quarter. But as investors ...

Zoetis exceeded market expectations in Q4 2024, with impressive financial performance despite challenges in specific segments ...

What Happened? Shares of animal health company Zoetis (NYSE:ZTS) fell 10.6% in the morning session after the company reported ...

BTIG lowered the firm’s price target on Zoetis (ZTS) to $200 from $225 and keeps a Buy rating on the shares. The company delivered an in-line ...

Zoetis received a USDA conditional license for its H5N2 avian flu vaccine for chickens, marking a step in addressing the ...

Phibro Animal Health projects strong 2025 revenue growth despite debt concerns. Read this artile to know why I think PAHC ...

Welcome to the fourth-quarter and full-year 2024 financial results conference call and webcast for Zoetis. Hosting the call today is Steve Frank, vice president of investor relations for Zoetis.